

Medicines Update: April 2026

This medicines update is provided by the Veterinary Medicines Directorate (VMD) and lists new active substance, new marketing authorisations and changes to authorisations most relevant to vets.

New marketing authorisations

Novel products

Scovella 15 mg/ml Oral Solution for Horses is the first veterinary medicinal product containing velagliflozin to be authorised in GB for use in horses. The product is specifically authorised for the treatment of hyperinsulinaemia in insulin-dysregulated horses and ponies not responsive to changes in husbandry and exercise regimen.

Zetbelis 10 mg Gastro-Resistant Capsules for Dogs is the first veterinary medicinal product containing omeprazole to be authorised in GB for use in dogs. The product is specifically authorised for use as an aid in the treatment of NSAID-induced gastric ulceration in dogs.

Table 1 shows the new marketing authorisations for April 2026

TABLE 1: New marketing authorisations in April 2026

New Marketing Authorisations			
Product name and target species	Active substance	Authorisation Holder, territory, and distribution category	Therapeutic group
Food Animals			
Cirbloc M Hyo Emulsion for Injection for Pigs	Mycoplasma hyopneumoniae, Porcine circovirus-2	Ceva Animal Health Ltd GB, POM-V	Inactivated Viral and Bacterial Vaccine
Nobilis Multiriva RT+IBm+ND+EDS Emulsion for Injection for Chickens	Avian metapneumovirus, Infectious bronchitis virus, Newcastle disease virus, Egg drop syndrome virus	MSD Animal Health UK Limited GB, POM-V	Inactivated Viral Vaccine
Nobilis Multiriva RT+IBm+ND+Gm+REOm Emulsion for Injection for Chickens	Avian metapneumovirus, Infectious bronchitis virus, Newcastle disease virus, Avian reovirus	MSD Animal Health UK Limited GB, POM-V	Inactivated Viral Vaccine

Noviderme 660 mg/g + 7.7 mg/g Cutaneous Ointment for Horses, Cattle and Sheep	Salicylic Acid, Methyl Salicylate	WDT-Wirtschaftsgenossenschaft deutscher Tierärzte eG NI, POM-V	Miscellaneous skin preparation
Optivar 500 mg Beehive Strips for Honey Bees	Amitraz	Veto-Pharma SAS GB & NI, AVM-GSL	Ectoparasiticide
Scovella 15 mg/ml Oral Solution for Horses	Velagliflozin	Boehringer Ingelheim Vetmedica GmbH GB, POM-V	Miscellaneous
Non-food Animals			
Zetbelis 10 mg Gastro-Resistant Capsules for Dogs	Omeprazole	TriviumVet DAC GB, POM-V	Gastrointestinal

See the VMD's [Product Information Database \(www.gov.uk/check-animal-medicine-licensed\)](http://www.gov.uk/check-animal-medicine-licensed) for more information on each of these products. There may be a delay before formal documentation is available for some Northern Ireland products, from the European Medicines Agency.

The timing of the product being placed on the market is an issue for the marketing authorisation holder.

Changes to authorisations most relevant to vets

The changes to authorisations most relevant to vets can be found below. Each product is listed, along with the authorisation holder, distribution category and details of which Summary of Product Characteristics (SPC) sections have been revised/changed.

Changes to the SPC, labels and leaflets may change how the medicines should be used. Details can be found on the VMD's Product Information Database (PID) at www.gov.uk/check-animal-medicine-licensed.

Due to ongoing assessments, there may be a delay between the point at which a new change is authorised and the updated SPC being available on the PID. There may also be a delay between the point at which any SPC changes are authorised and implementation in the product literature. Unless you have been advised otherwise, the labelling instructions on the pack which is dispensed should be followed.

Food producing animals

Flordofen 300 mg/ml Solution for Injection for Cattle and Pigs

Dopharma Research B.V. GB & NI POM-V

SPC Section 4.5 (GB) and 3.5 (NI) Special precautions for the protection of the environment: The use of this veterinary medicinal product may pose a risk for terrestrial plants, cyanobacteria and groundwater organisms.

Section 6.6 (GB) and 5.5 (NI) Disposal advice: The veterinary medicinal product should not enter water courses as florfenicol may be dangerous for fish and other aquatic organisms.

Florinject 300 mg/ml Solution for Injection for Cattle and Pigs

Laboratorios Calier, S.A. NI POM-V

SPC Section 3.5 Special precautions for the protection of the environment: The use of this veterinary medicinal product may pose a risk for terrestrial plants, cyanobacteria and groundwater organisms.

Section 5.5 Disposal advice: The veterinary medicinal product should not enter water courses as florfenicol may be dangerous for fish and other aquatic organisms.

Phenoxyphen Water Soluble Powder, 325 mg/g Powder for Oral Solution for Chickens (and Pigs)

Dopharma Research B.V. GB & NI POM-V

SPC Section 4.1: Addition of pigs as target species

Section 4.2: Treatment and metaphylaxis of infections caused by *Streptococcus suis*. The presence of the disease in the group must be established before the product is used.'

Information for use in pigs added to Sections: 4.9 Amounts to be administered and administration route, 4.11 Withdrawal periods, and 5.2 Pharmacokinetic particulars.

Section 4.4 Special warnings: Cross-resistance has been shown between phenoxymethylpenicillin and other beta-lactam antibiotics. Use of the product should be carefully considered when susceptibility testing has shown resistance to beta-lactam antibiotics because its effectiveness may be reduced.

Recocam 20 mg/ml Solution for Injection for Cattle, Pigs and Horses

Bimeda Animal Health Limited GB POM-V

SPC Section 3.2 added: For the relief of post-operative pain following dehorning in calves. Section 3.4 Special warnings: Treatment of calves with the veterinary medicinal product 20 minutes before dehorning reduces postoperative pain. The veterinary medicinal product alone will not provide adequate pain relief during the dehorning procedure. To obtain adequate pain relief during surgery co-medication with an appropriate analgesic is needed.

Regumate Equine 2.2 mg/ml Oral Solution for Horses

Intervet International B.V. GB & NI POM-V

SPC Section 3.5 Special precautions to be taken by the person administering the veterinary medicinal product to animals: Adverse reproductive effects reported in men include decreased libido.

Acute effects after single exposure are possible, but repeated accidental exposure has the potential for more adverse effects.

This veterinary medicinal product should not be handled by:

- persons with known or suspected breast cancer or other progesterone-dependent tumours
- persons with thrombo-embolic disorders or a history of those
- persons with cerebral-vascular or coronary-artery disease
- women with vaginal bleeding of unknown cause
- persons with liver dysfunction or disease.

People with known hypersensitivity to the active substance should avoid contact with the veterinary medicinal product.

Avoid contact with skin, eyes and oral ingestion due to hand-to-mouth contact.

Personal protective equipment consisting of overalls and chemical resistant single-use gloves (e.g. nitrile gloves) should be worn when handling the veterinary medicinal product. This veterinary medicinal product can penetrate latex or other types of porous gloves and absorption through the skin may be even higher when the area is covered by an occlusive material.

Do not eat, drink or smoke while handling the product.

Wash hands after use.

In case of accidental ingestion do not induce vomiting as pulmonary damage via aspiration of oil base may occur. Seek medical advice immediately and show the package leaflet or the label to the physician.

Any equipment or surfaces that come into contact with the veterinary medicinal product should be adequately cleaned and decontaminated to prevent human exposure. Wear gloves when cleaning.

VETERELIN 0.004 mg/ml Solution for Injection for Cattle, Horses, Pigs, and Rabbits

Laboratorios Calier, S.A. GB & NI POM-V

Revision of most sections of SPC including addition of information to Section 3.4 Special warnings, Section 3.5 Special precautions to be taken by the person administering the product, Section 3.7 Use during pregnancy, lactation, or lay, Section 3.9 Administration routes and dosage, and Section 4.3 Pharmacokinetics.

Companion animals

Nobivac KC (Dogs)

Intervet International B.V. GB POM-V

SPC section 4.5 Addition to Special precautions: Avoid accidental self-injection or contact with the eyes. In case of ocular irritation or accidental self-injection seek medical advice immediately and show the package leaflet or the label to the physician.

Strantel Plus XL Tablets for Dogs

Chanelle Pharmaceuticals Manufacturing Ltd NI NFA-VPS

SPC Section 3.6 Adverse events: addition of lethargy, anorexia, and hyperactivity with a frequency of very rare (<1 animal in 10,000 animals treated, including isolated reports).

Versican Plus DHPPi/L4 Lyophilisate and Suspension for Suspension for Injection for Dogs

Versican Plus DHPPi/L4R Lyophilisate and Suspension for Suspension for Injection for Dogs

Versican Plus L4 Suspension for Injection for Dogs

Versican Plus Pi/L4 Lyophilisate and Solvent for Suspension for Injection for Dogs

Versican Plus Pi/L4R Lyophilisate and Suspension for Suspension for Injection for Dogs

Zoetis UK Limited GB POM-V

SPC Section 4.6 Adverse events: Addition of 'Injection site lump', 'Injection site mass' and 'Injection site nodule' under frequency category 'Rare' (more than 1 but less than 10 animals in 10,000 treated).

For more information, contact the VMD at postmaster@vmd.gov.uk